These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 13130318)

  • 1. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation.
    Vij R; Khoury H; Brown R; Goodnough LT; Devine SM; Blum W; Adkins D; DiPersio JF
    Bone Marrow Transplant; 2003 Oct; 32(7):703-7. PubMed ID: 13130318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
    Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K
    Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
    Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
    Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
    Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
    Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
    Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kobayashi T; Takasugi K; Iseki T; Tojo A; Asano S
    Bone Marrow Transplant; 2008 Feb; 41(4):371-6. PubMed ID: 17982495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation.
    Singhal S; Mehta J; Powles R; Treleaven J; Horton C; Carrington D; Tryhorn Y; Jameson B
    Bone Marrow Transplant; 1995 May; 15(5):777-81. PubMed ID: 7670405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
    Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
    Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
    Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.
    Kim DH; Kim JG; Lee NY; Sung WJ; Sohn SK; Suh JS; Lee KS; Lee KB
    Bone Marrow Transplant; 2004 Jul; 34(1):21-7. PubMed ID: 15133483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation.
    Stocchi R; Szydlo R; Craddock C; Kanfer E; Apperley JF; Goldman JM; Ward KN
    Bone Marrow Transplant; 1999 Apr; 23(7):705-9. PubMed ID: 10218848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
    Walker CM; van Burik JA; De For TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
    Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.